SEARCH:   Advanced

Blood, 15 November 2003, Vol. 102, No. 10, pp. 3569-3574. Prepublished online as a Blood First Edition Paper on July 31, 2003; DOI 10.1182/blood-2003-03-0919. This Article Full Text Full Text (PDF) All Versions of this Article: 2003-03-0919v1 102/10/3569    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Klippel, S. Articles by Pahl, H. L. Search for Related Content PubMed PubMed Citation Articles by Klippel, S. Articles by Pahl, H. L. Related Collections Hematopoiesis and Stem Cells Neoplasia Gene Therapy Related Letter in Blood Online Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  HEMATOPOIESIS Quantification of PRV-1 mRNA distinguishes polycythemia vera from secondary erythrocytosis Steffen Klippel, Elisabeth Strunck, Snezana Temerinac, Anthony J. Bench, Gerold Meinhardt, Ursula Mohr, Rosi Leichtle, Anthony R. Green, Martin Griesshammer, Hermann Heimpel, and Heike L. Pahl From the Department of Experimental Anaesthesiology, University Hospital Freiburg, Center for Clinical Research, Freiburg, Germany; the Department of Hematology/Oncology, Klinikum Innenstadt, Ludwig-Maximilians-Universität München, München, Germany; the Department of Hematology/Oncology, University Hospital Freiburg, Freiburg, Germany; the Department of Hematology and Oncology, University Hospital Ulm, Ulm, Germany; and the Department of Haematology, University of Cambridge, Cambridge Institute for Medical Research, Cambridge, United Kingdom. To date, the diagnosis of polycythemia vera (PV) relies on clinical criteria. We have recently described the overexpression of a hematopoietic receptor, polycythemia rubra vera-1 (PRV-1), in patients with PV. Here, we report a quantitative reverse transcriptase-polymerase chain reaction (RT-PCR) assay for the measurement of PRV-1 mRNA levels. We have determined PRV-1 expression in 71 patients with PV, 11 patients with secondary erythrocytosis (SE), as well as in 80 healthy controls. PV patients express significantly higher amounts of PRV-1 than healthy controls or patients with SE (P < .0001). Because there is no overlap between the PRV-1 expression in PV patients versus healthy controls or SE patients, the assay has a very high sensitivity and specificity for the diagnosis of PV in our population. In patients with erythrocytosis, the quantitative RT-PCR assay described here therefore provides a rapid, highly specific and sensitive tool for the diagnosis of PV. (Blood. 2003;102: 3569-3574) CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? Related Letter in Blood Online: Usefulness of the quantitative assessment of PRV-1 gene expression for the diagnosis of polycythemia vera and essential thrombocythemia patients Daniela Cilloni, Sonia Carturan, Enrico Gottardi, Francesca Messa, Milena Fava, Ilaria Defilippi, Francesca Arruga, Giuseppe Saglio, Steffen Klippel, Philipp S. Goerttler, and Heike L. Pahl Blood 2004 103: 2428-2429. [Full Text] [PDF] This article has been cited by other articles: E. Antonioli, P. Guglielmelli, G. Poli, C. Bogani, A. Pancrazzi, G. Longo, V. Ponziani, L. Tozzi, L. Pieri, V. Santini, et al. Influence of JAK2V617F allele burden on phenotype in essential thrombocythemia Haematologica, January 1, 2008; 93(1): 41 - 48. [Abstract] [Full Text] [PDF] S. Rives, H. L. Pahl, L. Florensa, B. Bellosillo, A. Neusuess, J. Estella, K.-M. Debatin, E. Kohne, K. Schwarz, and H. Cario Molecular genetic analyses in familial and sporadic congenital primary erythrocytosis Haematologica, May 1, 2007; 92(5): 674 - 677. [Abstract] [Full Text] [PDF] E. Hammond, K. Shaw, B. Carnley, S. P'ng, I. James, and R. Herrmann Quantitative Determination of JAK2 V617F by TaqMan: An Absolute Measure of Averaged Copies per Cell That May Be Associated with the Different Types of Myeloproliferative Disorders J. Mol. Diagn., April 1, 2007; 9(2): 242 - 248. [Abstract] [Full Text] [PDF] E. Lippert, M. Boissinot, R. Kralovics, F. Girodon, I. Dobo, V. Praloran, N. Boiret-Dupre, R. C. Skoda, and S. Hermouet The JAK2-V617F mutation is frequently present at diagnosis in patients with essential thrombocythemia and polycythemia vera Blood, September 15, 2006; 108(6): 1865 - 1867. [Abstract] [Full Text] [PDF] R. Kralovics, S.-S. Teo, A. S. Buser, M. Brutsche, R. Tiedt, A. Tichelli, F. Passamonti, D. Pietra, M. Cazzola, and R. C. Skoda Altered gene expression in myeloproliferative disorders correlates with activation of signaling by the V617F mutation of Jak2 Blood, November 15, 2005; 106(10): 3374 - 3376. [Abstract] [Full Text] [PDF] P. S. Goerttler, C. Steimle, E. Marz, P. L. Johansson, B. Andreasson, M. Griesshammer, H. Gisslinger, H. Heimpel, and H. L. Pahl The Jak2V617F mutation, PRV-1 overexpression, and EEC formation define a similar cohort of MPD patients Blood, October 15, 2005; 106(8): 2862 - 2864. [Abstract] [Full Text] [PDF] A. Tefferi and D. G. Gilliland The JAK2V617F Tyrosine Kinase Mutation in Myeloproliferative Disorders: Status Report and Immediate Implications for Disease Classification and Diagnosis Mayo Clin. Proc., July 1, 2005; 80(7): 947 - 958. [Abstract] [PDF] A. M. Ferraris, R. Mangerini, N. Pujic, O. Racchi, D. Rapezzi, A. Gallamini, S. Casciaro, and G. F. Gaetani High telomerase activity in granulocytes from clonal polycythemia vera and essential thrombocythemia Blood, March 1, 2005; 105(5): 2138 - 2140. [Abstract] [Full Text] [PDF] S. Sirhan, T. L. Lasho, and A. Tefferi Clinical and Laboratory Correlative Studies of Neutrophil PRV-1 Expression: A Prospective Study in 141 Subjects. Blood (ASH Annual Meeting Abstracts), November 16, 2004; 104(11): 1519 - 1519. [Abstract] [Full Text] S. Sirhan, T. L. Lasho, M. A. Elliott, and A. Tefferi Neutrophil and Eosinophil PRV-1 Expression in Atypical Myeloproliferative Disorders. Blood (ASH Annual Meeting Abstracts), November 16, 2004; 104(11): 1521 - 1521. [Abstract] L. Teofili, M. Martini, F. Guidi, D. Venditti, G. Leone, and M. L. Larocca The PRV-1 gene expression in essential thrombocythemia Blood, November 1, 2004; 104(9): 2995 - 2996. [Full Text] [PDF] A. Tefferi, T. L. Lasho, A. P. Wolanskyj, and R. A. Mesa Neutrophil PRV-1 expression across the chronic myeloproliferative disorders and in secondary or spurious polycythemia Blood, May 1, 2004; 103(9): 3547 - 3548. [Abstract] [Full Text] [PDF] D. Cilloni, S. Carturan, E. Gottardi, F. Messa, M. Fava, I. Defilippi, F. Arruga, G. Saglio, S. Klippel, P. S. Goerttler, et al. Usefulness of the quantitative assessment of PRV-1 gene expression for the diagnosis of polycythemia vera and essential thrombocythemia patients Blood, March 15, 2004; 103(6): 2428 - 2429. [Full Text] [PDF] L. Palmqvist, P. Goerttler, C. Wasslavik, P. Johansson, B. Andreasson, S. Safai-Kutti, J. Kutti, H. L. Pahl, and A. Ricksten Comparison of Methods for Polycythemia Rubra Vera-1 mRNA Quantification in Whole-Blood Leukocytes and Purified Granulocytes Clin. Chem., March 1, 2004; 50(3): 644 - 647. [Full Text] [PDF] A. Tefferi Polycythemia Vera Evaluation Algorithm Revisited-Reply-I Mayo Clin. Proc., March 1, 2004; 79(3): 430 - 431. [PDF]

	Copyright © 2003 by American Society of Hematology         Online ISSN: 1528-0020